Disparities and Delay in the Use of Guideline-Based Antiretroviral Therapy for Treatment of Pregnant Women with HIV in the Southeast United States

Cocohoba J , Wang QJ , Cox C , et al. Consistency of initial antiretroviral therapy with HIV treatment guidelines in a US cohort of HIV-infected women. J Acquir Immune Defic Syndr, 2008; 47:377–383.

Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. U.S. Public Health Service Task Force Recommendations for the Use of Antiretroviral Drugs in Pregnant Women Infected with HIV-1 for Maternal Health and for Reducing Perinatal HIV-1 Transmission in the United States. United States Department of Health and Human Services. 2000.

Gebo KA , Fleishman JA , Conviser R , et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr, 2005; 38:96–103.

Cocohoba JM , Althoff KN , Godfrey R , Palella FJ , Greenblatt RM . Influence of gender on receipt of guideline-based antiretroviral therapy in the era of HAART. AIDS Care, 2012; 24:20–29.

Wandeler G , Keiser O , Hirschel B , et al. A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA. PLoS One, 2011; 6:e27903.

Beer L , Mattson CL , Bradley H , Skarbinski J ; Medical Monitoring Project. Understanding cross-sectional racial, ethnic, and gender disparities in antiretroviral use and viral suppression among HIV patients in the United States. Medicine (Baltimore), 2016; 95:e3171.

Tubiana R , Le Chenadec J , Rouzioux C , et al. Factors associated with mother-to-child transmission of HIV-1 despite a maternal viral load <500 copies/ml at delivery: A case-control study nested in the French perinatal cohort (EPF-ANRS CO1). Clin Infect Dis, 2010; 50:585–596.

Lazenby GB , Powell AM , Sullivan SA , Soper DE . The impact of delivery in a rural county on a cohort of women living with HIV infection and their infants. J Rural Health, 2019; 35:319–329.

Centers for Disease Control and Prevention. eHARS v4.7 Technical Reference Guide. In: National Center for HIV/AIDS VH, STD and TB Prevention Division of HIV/AIDS Prevention. Quantitative Sciences and Data Management Branch, ed. 2015.

Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States: United States Department of Health and Human Services. 2014.

Centers for Disease Control and Prevention. Revised surveillance case definition for HIV infection—United States, 2014. MMWR Recomm Rep, 2014; 63:1–10.

Llibre JM , Hung CC , Brinson C , et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: Phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet, 2018; 391:839–849.